March 27 Colombian airline Avianca countersued its No. 2 shareholder on Monday, escalating a battle over a plan by top shareholder Synergy Group Corp to forge an alliance with United Continental Holdings Inc.
Avianca's motion seeks to dismiss claims in a lawsuit filed by Kingsland Ltd earlier this month and opposes Kingsland’s motion for an injunction to stop the United negotiations.
"Avianca has at all times performed its role under the parties’ shareholder agreement, while Kingsland has explicitly breached its obligations," a statement issued by the company said. "Avianca points out that Kingsland’s legal maneuvers are a heavy-handed attempt to obtain greater rights in the courtroom than it previously negotiated for and agreed to in the parties’ shareholder agreement."
The countersuit by Avianca asks the court for an order preventing Kingsland from any further dissemination of the company’s "confidential information, requiring Kingsland to comply with the dispute resolution section of the parties’ shareholder agreement, and requiring Kingsland’s representatives to cease interfering with the shareholder agreement."
Kingsland and Avianca were set to meet in New York State Supreme Court on Tuesday so a judge could rule on Kingland's petition for a preliminary injuction. However, a representative for Kingsland told Reuters the court date had been moved to April 2.
Kingsland, which holds about 22 percent of Avianca's voting shares and 14 percent of total shares, said in the suit it is seeking "injunctive relief to prevent the cabal of insiders that controls Avianca ... from proceeding with their unlawful attempt to ram through the egregiously one-sided United Transaction in order to divert hundreds of millions of dollars to themselves in violation of their fiduciary and contractual duties."
Synergy holds 78 percent of Avianca voting shares.
Kingsland did not immediately respond to a request for comment. (Reporting by Dion Rabouin; Editing by Marguerita Choy)
BRIEF-Sherwin-Williams proposes offering of $1.48 bln senior notes - SEC filing
* Proposes offering of $1.48 billion senior notes - SEC filing Source text: (http://bit.ly/2t2zU6x) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)
BRIEF-Horizon Pharma sees 2017 net sales between $985 mln - $1.02 bln
* Full-year 2017 net sales are now expected to be in a range of $985 million to $1.020 billion